Compare AbbVie Inc (ABBV) vs VanEck JP Morgan EM Local Currency Bond ETF (EMLC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs VanEck JP Morgan EM Local Currency Bond ETF — how do they compare? AbbVie Inc trades at $253.68 (market cap $449.91B), while VanEck JP Morgan EM Local Currency Bond ETF trades at $25.37. The key difference: AbbVie Inc pays a 2.72% dividend while VanEck JP Morgan EM Local Currency Bond ETF pays none, and AbbVie Inc is trading nearer its 52-week high, VanEck JP Morgan EM Local Currency Bond ETF nearer its low. Which is the better fit depends on your goals.
| ABBV | EMLC | |
|---|---|---|
Market Cap | $449.91B | — |
Sector | Health | Fixed Income |
52-Week High | $261.07 | $26.59 |
52-Week Low | $184.85 | $24.83 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
EMLC trades at $25.59 with a modest 0.51% daily gain, showing bullish technical momentum with strong moving average support. The ETF maintains a consistent dividend distribution pattern with recent $0.14 payouts, while technical indicators show mixed signals with RSI in neutral territory. Emerging market debt remains in focus as investors seek yield above Treasury bonds amid shifting global monetary policy.
The outlook for EMLC hinges on Federal Reserve policy and emerging market stability. The 6.09% yield provides income appeal, but currency risk and short interest growth present challenges. Institutional demand for EM debt is rising, though sustainability concerns warrant monitoring given the 73% short interest surge reported in April 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About VanEck JP Morgan EM Local Currency Bond ETF
EMLC invests in local currency-denominated government bonds from emerging market countries. It provides exposure to sovereign debt in nations like Brazil, Mexico, and South Africa, allowing investors to gain from high yields and potential local currency appreciation.
Read more on EMLC →
